{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:57:47Z","timestamp":1783115867748,"version":"3.54.6"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001801","name":"University of Western Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Diabetes Metab Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Octreotide is second-line treatment for patients with congenital hyperinsulinism (CHI) unresponsive to diazoxide. Short-acting octreotide is administered via subcutaneous (SC) injection or continuous infusion using a pump, but limited data exist on pump therapy. We present two cases of CHI managed with an octreotide infusion via pump with or without concurrent continuous glucose monitoring (CGM), providing practical guidance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Octreotide 500mcg\/1ml ampoule was used. The starting dose was 5mcg\/kg\/day, with titration to optimize glycaemia, and delivered as a continuous basal rate using a pump. CGM was used by Patient 2.<\/jats:p>\n                    <jats:p>\n                      Patient 1: CHI due to a paternal\n                      <jats:italic>ABCC8<\/jats:italic>\n                      mutation was detected at 16 weeks of age, with diffuse uptake on 18F-DOPA PET. Unresponsive to diazoxide, SC octreotide injections commenced, transitioning to an infusion (13mcg\/kg\/day) with good response, and complete cessation of therapy at four years.\n                    <\/jats:p>\n                    <jats:p>Patient 2: Neonate with CHI due to Beckwith Wiedemann Syndrome developed side-effects from diazoxide and was commenced on SC octreotide injections. Effective at 30mcg\/kg\/day, he transitioned to an infusion at 4.5 months followed by long-acting octreotide at 12 months.<\/jats:p>\n                    <jats:p>Both patients tolerated the infusion with no adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This report highlights the practical use of octreotide infusion via pump. When combined with CGM, it allows for tailored dosing to meet individual needs while enhancing patient convenience.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40200-025-01709-2","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:52:48Z","timestamp":1760172768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Continuous subcutaneous octreotide infusion in congenital hyperinsulinism: practical application and insights in infancy and early childhood"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8414-4479","authenticated-orcid":false,"given":"Mercedes J.","family":"Burnside","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Stafford-Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Romans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Moller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine S.","family":"Choong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary B.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"1709_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-63","volume":"6","author":"JB Arnoux","year":"2011","unstructured":"Arnoux JB, Verkarre V, Saint-Martin C, Montravers F, Brassier A, Valayannopoulos V, et al. Congenital hyperinsulinism: current trends in diagnosis and therapy. Orphanet J Rare Dis. 2011;6:63.","journal-title":"Orphanet J Rare Dis"},{"key":"1709_CR2","first-page":"1017","volume":"62","author":"M G\u00fcemes","year":"2015","unstructured":"G\u00fcemes M, Hussain K. Hyperinsulinemic hypoglycaemia. Pediatr Clin. 2015;62:1017\u201336.","journal-title":"Pediatr Clin"},{"key":"1709_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00111","volume":"10","author":"S Galcheva","year":"2019","unstructured":"Galcheva S, Demirbilek H, Al-Khawaga S, Hussain K. The genetic and molecular mechanisms of congenital hyperinsulinism. Front Endocrinol. 2019;10:111.","journal-title":"Front Endocrinol"},{"key":"1709_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000531766","volume":"97","author":"DD De Leon","year":"2024","unstructured":"De Leon DD, Arnoux JB, Banerjee I, Bergada I, Bhatti T, Conwell LS, et al. International guidelines for the diagnosis and management of hyperinsulinism. Horm Res Paediatr. 2024;97:279\u201398.","journal-title":"Horm Res Paediatr"},{"key":"1709_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/cen.12075","volume":"78","author":"T Yorifuji","year":"2013","unstructured":"Yorifuji T, Kawakita R, Hosokawa Y, Fujimaru R, Matsubara K, Aizu K, et al. Efficacy and safety of long-term, continuous subcutaneous octreotide infusion for patients with different subtypes of KATP-channel hyperinsulinism. Clin Endocrinol. 2013;78:891\u20137.","journal-title":"Clin Endocrinol"},{"issue":"4","key":"1709_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0022-3476(05)80969-2","volume":"123","author":"PS Thornton","year":"1993","unstructured":"Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA. Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr. 1993;123(4):637\u201343.","journal-title":"J Pediatr"},{"key":"1709_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/2042018820965068","author":"B Haris","year":"2020","unstructured":"Haris B, Saraswathi S, Hussain K. Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia. Ther Adv Endocrinol Metab. 2020. https:\/\/doi.org\/10.1177\/2042018820965068.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"2","key":"1709_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000485184","volume":"89","author":"I Van der Steen","year":"2018","unstructured":"Van der Steen I, Van Albada ME, Mohnike K, Christesen HT, Empting S, Salomon-Estebanez M, et al. A multicenter experience with long-acting somatostatin analogues in patients with congenital hyperinsulinism. Horm Res Paediatr. 2018;89(2):82\u20139.","journal-title":"Horm Res Paediatr"},{"issue":"12","key":"1709_CR9","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1310967","volume":"370","author":"S Senniappan","year":"2014","unstructured":"Senniappan S, Alexandrescu S, Tatevian N, Shah P, Arya V, Flanagan S, et al. Sirolimus therapy in infants with severe hyperinsulinemic hypoglycaemia. N Engl J Med. 2014;370(12):1131\u20137.","journal-title":"N Engl J Med"},{"issue":"9","key":"1709_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1507\/endocrj.EJ17-0024","volume":"64","author":"Y Hosokawa","year":"2017","unstructured":"Hosokawa Y, Kawakita R, Yokoya S, Ogata T, Ozono K, Arisaka O, et al. Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry. Endocr J. 2017;64(9):867\u201380.","journal-title":"Endocr J"},{"issue":"3","key":"1709_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1297\/cpe.26.127","volume":"26","author":"T Yorifuji","year":"2017","unstructured":"Yorifuji T, Horikawa R, Hasegawa T, Adachi M, Soneda S, Minagawa M, et al. Clinical practice guidelines for congenital hyperinsulinism. Clin Pediatr Endocrinol. 2017;26(3):127\u201352.","journal-title":"Clin Pediatr Endocrinol"},{"issue":"8","key":"1709_CR12","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1515\/jpem-2022-0643","volume":"36","author":"V Tiberi","year":"2023","unstructured":"Tiberi V, Cherubini V, Iannilli A, Gasparini F, Marino M. Adjustment of octreotide dose given via insulin pump based on continuous glucose monitoring (CGM) in a child with congenital hyperinsulinism. J Pediatr Endocrinol Metab. 2023;36(8):803\u20137.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"1709_CR13","volume-title":"ASHP\u00ae injectable drug information\u2122","author":"M Gabay","year":"2025","unstructured":"Gabay M, Rosanelli NC, Rallo A. ASHP\u00ae injectable drug information\u2122. 2025th ed. Bethesda: American Society of Health-System Pharmacists; 2025.","edition":"2025"},{"key":"1709_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1530\/EJE-11-0874","volume":"166","author":"KH Le Quan Sang","year":"2012","unstructured":"Le Quan Sang KH, Arnoux JB, Mamoune A, Saint-Martin C, Bellanne-Chantelot C, Valayannopoulos V, et al. Successful treatment of congenital hyperinsulinism with long-acting release octreotide. Eur J Endocrinol. 2012;166:333\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"1709_CR15","doi-asserted-by":"publisher","first-page":"e3115","DOI":"10.1210\/clinem\/dgac322","volume":"107","author":"H Cuff","year":"2022","unstructured":"Cuff H, Lord K, Ballester L, Scully T, Stewart N, De Leon DD. The use of Lanreotide in the treatment of congenital hyperinsulinism. J Clin Endocrinol Metab. 2022;107(8):e3115\u201320.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1709_CR16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S0022-3476(05)80970-9","volume":"123","author":"B Glaser","year":"1993","unstructured":"Glaser B, Hirsch HJ, Landau H. Persistent hyperinsulinemic hypoglycaemia of infancy: long-term octreotide treatment without pancreatectomy. J Pediatr. 1993;123(4):644\u201350.","journal-title":"J Pediatr"},{"key":"1709_CR17","doi-asserted-by":"crossref","unstructured":"Melikyan MA, Gubaeva DN, Kareva MA. Continuous subcutaneous infusion of somatostatin analogues in the treatment of congenital hyperinsulinism. Probl Endokrinol (Mosk). 2020;66(3):81\u201387. Published 2020 Sep 16.","DOI":"10.14341\/probl12421"},{"key":"1709_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0367-x","volume":"10","author":"A Welters","year":"2015","unstructured":"Welters A, Lerch C, Kummer S, Marquard J, Salgin B, Mayatepek E, et al. Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers. Orphanet J Rare Dis. 2015;10:150.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Journal of Diabetes &amp; Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40200-025-01709-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40200-025-01709-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40200-025-01709-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:55:10Z","timestamp":1767495310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40200-025-01709-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1709"],"URL":"https:\/\/doi.org\/10.1007\/s40200-025-01709-2","relation":{},"ISSN":["2251-6581"],"issn-type":[{"value":"2251-6581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not required for this case report as per the Human Research Ethics Committee procedures of the hospital. This retrospective review of patient data did not require ethical approval in accordance with local guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study approval"}},{"value":"Written informed consent was obtained from the legal guardians of the participants included in this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent was obtained from the legal guardians of the participants for publication of the details of their medical case.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}